Patents by Inventor Matthew WAKE

Matthew WAKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment for physiological iron overload with an anti-matriptase-2 antibody
    Patent number: 12570740
    Abstract: Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: March 10, 2026
    Assignee: Kymab Limited
    Inventors: Matthew Wake, Volker Germaschewski, Igor Theurl, Jonathan Leslie Papworth, Delphine Meynard
  • TREATMENT FOR PHYSIOLOGICAL IRON OVERLOAD
    Publication number: 20230025129
    Abstract: Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 26, 2023
    Inventors: Matthew WAKE, Volker GERMASCHEWSKI, Igor THEURL, Jonathan Leslie PAPWORTH, Delphine MEYNARD